Related Experiment Video
Updated: Feb 21, 2026
08:52
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.7K
Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry
Mark Slomiany1, Priya Madhavan2, Michael Kuehn3
1Consultant, Market Access Health, GfK, New York, NY.
American Health & Drug Benefits
|October 5, 2017
Summary
Value frameworks in oncology are emerging to address rising costs. While awareness and use vary, stakeholders anticipate increased utility as these tools become more established.
Area of Science:
- Oncology
- Health Economics
- Value-Based Care
Background:
- Rising costs of cancer care necessitate new value assessment models.
- Diverse stakeholder concerns (patients, physicians, payers, policymakers, industry) shape these models.
Purpose of the Study:
- To review and compare the capabilities and limitations of five prominent oncology value frameworks.
- To assess the relative value and application of these frameworks for various stakeholders.
Main Methods:
- Comparative analysis of framework methodology (input, scoring, output).
- Inclusion of stakeholder insights via physician/payer dialogues and secondary research.
- Evaluation of American Society of Clinical Oncology (ASCO) Value Framework, National Comprehensive Cancer Network Evidence Blocks, Memorial Sloan Kettering Cancer Center DrugAbacus, Institute for Clinical and Economic Review Value Assessment Framework, and European Society for Medical Oncology Magnitude of Clinical Benefit Scale.
Main Results:
- Frameworks differ in focus on clinical trial elements, evidence breadth, and weighting.
- Physician awareness and utilization of frameworks currently vary.
- Physicians anticipate greater future utility of value frameworks as they mature.
Conclusions:
- Physicians, policymakers, patients, and payers are actively defining value in oncology.
- Pharmaceutical companies are assessing framework impact on drug value and cost thresholds.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
18.6K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.7K
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
491
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
491
01:21Cancer Survival Analysis
793
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
793
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
01:16Bioequivalence: Overview
2.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.1K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K